In a recent study on a Chinese CRC cohort, the authors concluded that an NRAS mutation is an independent prognostic marker for distant metastasis in stage I–III patients, with shorter metastasis-free intervals than NRAS wild-type patients [33]. This evidence concerns the gene NRAS and colorectal carcinoma.